Merck & Co Inc
MRK:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 46.75 | -0.54 -1.14% | 3.64% | 20,674,523 | 15.8M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Merck & Co Inc
Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
Merck and Endocyte's Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing
WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--October 14, 2013--
Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. These trial results are the basis for the vintafolide regulatory application currently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Enrollment is ongoing in the pivotal Phase III PROCEED clinical trial with vintafolide, along with investigational companion imaging agent etarfolatide (EC20), in platinum-resistant ovarian cancer (Clinicaltrials.gov NCT01170650).
Results of Phase II PRECEDENT Trial for -2-
View more recent headlines
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Company Background
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Effective February 25, 2013, Dashtag, a unit of Merck & Co Inc's Schering Plough Corp subsidiary acquired 17.95% interest in Fulford (India) Ltd.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 46.80 | Previous Close 47.29 |
Day High 47.08 | Day Low 46.44 |
52wk High/Date 50.16 / 6/4/2013 | 52wk Low/Date 40.02 / 12/31/2012 |
% off 52wk High -6.80% | % off 52wk Low 16.82% |
Beta (5 Yr) 0.6 | Market Capitalization 136.8B |
Shares Outstanding 2.9B | Volatility Avg 17.27 |
EPS(TTM) 1.68 | P/E Ratio 27.8 |
Dividend Announcement 7/24/2013 | Dividend Yield 3.64% |
Ex-Date 9/12/2013 | Date of Record 9/16/2013 |
Payable 0.43 - QRTR | Payable Date 10/7/2013 |
Last Trade as of 10/14/2013 4:00 PM ET | |
MRK Merck & Co Inc vs. Peers
| Peers | |
|---|---|
MRK Merck & Co Inc | 15.51% |
Johnson & Johnson | 27.60% |
Pfizer Inc. | 14.52% |
Abbott Laboratories | 7.72% |
Eli Lilly & Co. | -0.89% |
MRK Merck & Co Inc | 3.68% |
Johnson & Johnson | 2.95% |
Pfizer Inc. | 3.34% |
Abbott Laboratories | 1.66% |
Eli Lilly & Co. | 4.01% |
MRK Merck & Co Inc | -1.14% |
Johnson & Johnson | 0.39% |
Pfizer Inc. | 2.19% |
Abbott Laboratories | 0.71% |
Eli Lilly & Co. | 0.31% |